Literature DB >> 12869219

Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses.

Rima Youil1, Timothy J Toner, Qin Su, Danilo Casimiro, John W Shiver, Ling Chen, Andrew J Bett, Bethany M Rogers, Eric C Burden, Aimin Tang, Michelle Chen, Emilio A Emini, David C Kaslow, John G Aunins, Nedim E Altaras.   

Abstract

First-generation adenovectors have been developed for gene therapy and vaccine applications. The construction of these adenovectors has entailed the use of numerous types of expression cassettes. It has long been known that first-generation adenovectors can be rescued more easily and to higher titers with some transgenes than with others. This study has systematically shown that there can be marked differences in growth properties of recombinant adenovectors attributable to the use of promoters, the orientation of the transgene within the E1A/E1B-deleted region, and the inclusion of the E3 region. In addition, we had demonstrated the benefit of extending the packaging signal region to include elements V, VI, and VII. The effects of the complete packaging region were studied by plasmid competition studies between original and modified adenovectors. Similar competition studies between E3(+) and E3(-) adenovectors were performed and showed that the E3(+) vector had a growth advantage over its E3(-) counterpart. By making various changes, we have enhanced the growth capacity of our recombinant adenovector by more than 3-fold under serum-free and cell suspension growth conditions. Along with this enhanced growth, our adenovectors have maintained their genetic stability after 21 successive passages in cell culture. This increased robustness will be critical when adapting first-generation recombinant adenovectors to commercial production.

Mesh:

Substances:

Year:  2003        PMID: 12869219     DOI: 10.1089/104303403766682278

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  13 in total

1.  Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

Authors:  Lauren A Hirao; Ling Wu; Abhishek Satishchandran; Amir S Khan; Ruxandra Draghia-Akli; Adam C Finnefrock; Andrew J Bett; Michael R Betts; Danilo R Casimiro; Niranjan Y Sardesai; J Joseph Kim; John W Shiver; David B Weiner
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

2.  A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.

Authors:  Stefania Capone; Annalisa Meola; Bruno Bruni Ercole; Alessandra Vitelli; Monica Pezzanera; Lionello Ruggeri; Mary Ellen Davies; Rosalba Tafi; Claudia Santini; Alessandra Luzzago; Tong-Ming Fu; Andrew Bett; Stefano Colloca; Riccardo Cortese; Alfredo Nicosia; Antonella Folgori
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge.

Authors:  Danilo R Casimiro; Kara Cox; Aimin Tang; Kara J Sykes; Meizhen Feng; Fubao Wang; Andrew Bett; William A Schleif; Xiaoping Liang; Jessica Flynn; Timothy W Tobery; Keith Wilson; Adam Finnefrock; Lingyi Huang; Salvatore Vitelli; Jing Lin; Deepa Patel; Mary-Ellen Davies; Gwendolyn J Heidecker; Daniel C Freed; Sheri Dubey; David H O'Connor; David I Watkins; Zhi-Qiang Zhang; John W Shiver
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

4.  An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors.

Authors:  Daniele Catalucci; Elisabetta Sporeno; Agostino Cirillo; Gennaro Ciliberto; Alfredo Nicosia; Stefano Colloca
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.

Authors:  Matthew G Cottingham; Fionnadh Carroll; Susan J Morris; Alison V Turner; Aisling M Vaughan; Melissa C Kapulu; Stefano Colloca; Loredana Siani; Sarah C Gilbert; Adrian V S Hill
Journal:  Biotechnol Bioeng       Date:  2011-11-06       Impact factor: 4.530

6.  Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.

Authors:  Danilo R Casimiro; Andrew J Bett; Tong-ming Fu; Mary-Ellen Davies; Aimin Tang; Keith A Wilson; Minchun Chen; Romnie Long; Troy McKelvey; Michael Chastain; Sanjay Gurunathan; Jim Tartaglia; Emilio A Emini; John Shiver
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Authors:  Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark J Mulligan; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

8.  Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Authors:  Samuel O Pine; James G Kublin; Scott M Hammer; Joleen Borgerding; Yunda Huang; Danilo R Casimiro; M Juliana McElrath
Journal:  PLoS One       Date:  2011-04-13       Impact factor: 3.240

Review 9.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

10.  Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line.

Authors:  James M Wagner; J David Pajerowski; Christopher L Daniels; Patrick M McHugh; Jessica A Flynn; John W Balliet; Danilo R Casimiro; Shyamsundar Subramanian
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.